Seeding of Proteins into Amyloid Structures by Metabolite Assemblies May Clarify Certain Unexplained Epidemiological Associations

Overview

Journal Open Biol

Specialties Biology
Cell Biology
Molecular Biology

Date 2018 Jan 26

PMID 29367352

Citations 14

Authors

Dorin Sade

Shira Shaham-Niv

Zohar A Arnon

Omid Tavassoly

Ehud Gazit

Affiliations

Soon will be listed here.

Abstract

The accumulation of various metabolites appears to be associated with diverse human diseases. However, the aetiological link between metabolic alteration and the observed diseases is still elusive. This includes the correlation between the abnormally high levels of homocysteine and quinolinic acid in Alzheimer's disease, as well as the accumulation of oncometabolites in malignant processes. Here, we suggest and discuss a possible mechanistic insight into metabolite accumulation in conditions such as neurodegenerative diseases and cancer. Our hypothesis is based on the demonstrated ability of metabolites to form amyloid-like structures in inborn error of metabolism disorders and the potential of such metabolite amyloids to promote protein aggregation. This notion can provide a new paradigm for neurodegeneration and cancer, as both conditions were linked to loss of function due to protein aggregation. Similar to the well-established observation of amyloid formation in many degenerative disorders, the formation of amyloids by tumour-suppressor proteins, including p53, was demonstrated in malignant states. Moreover, this new paradigm could fill the gap in understanding the high occurrence of specific types of cancer among genetic error of metabolism patients. This hypothesis offers a fresh view on the aetiology of some of the most abundant human maladies and may redirect the efforts towards new therapeutic developments.

Citing Articles

Doxorubicin catalyses self-assembly of p53 by phase separation.

Garg A, Kumar G, Singh V, Sinha S Curr Res Struct Biol. 2024; 7:100133.

PMID: 38435052 PMC: 10906149. DOI: 10.1016/j.crstbi.2024.100133.

Chemical catalysis by biological amyloids.

Wittung-Stafshede P Biochem Soc Trans. 2023; 51(5):1967-1974.

PMID: 37743793 PMC: 10657172. DOI: 10.1042/BST20230617.

Mechanisms and pathology of protein misfolding and aggregation.

Louros N, Schymkowitz J, Rousseau F Nat Rev Mol Cell Biol. 2023; 24(12):912-933.

PMID: 37684425 DOI: 10.1038/s41580-023-00647-2.

The Crosstalk between HepG2 and HMC-III Cells: In Vitro Modulation of Gene Expression with Conditioned Media.

Koshal P, Matera I, Abruzzese V, Ostuni A, Bisaccia F Int J Mol Sci. 2022; 23(22).

PMID: 36430920 PMC: 9696318. DOI: 10.3390/ijms232214443.

Novel Therapeutic Target for Prevention of Neurodegenerative Diseases: Modulation of Neuroinflammation with Sig-1R Ligands.

Bogar F, Fulop L, Penke B Biomolecules. 2022; 12(3).

PMID: 35327555 PMC: 8945408. DOI: 10.3390/biom12030363.

References

Espey M, Chernyshev O, Reinhard Jr J, Namboodiri M, Colton C . Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport. 1997; 8(2):431-4. DOI: 10.1097/00001756-199701200-00011. View

Gazit E . Metabolite amyloids: a new paradigm for inborn error of metabolism disorders. J Inherit Metab Dis. 2016; 39(4):483-8. DOI: 10.1007/s10545-016-9946-9. View

Shmueli M, Schnaider L, Rosenblum D, Herzog G, Gazit E, Segal D . Structural insights into the folding defects of oncogenic pVHL lead to correction of its function in vitro. PLoS One. 2013; 8(6):e66333. PMC: 3688787. DOI: 10.1371/journal.pone.0066333. View

Yoshimoto Y, Nakaso K, Nakashima K . L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells. FEBS Lett. 2005; 579(5):1197-202. DOI: 10.1016/j.febslet.2004.12.091. View

Tan L, Yu J, Tan L . The kynurenine pathway in neurodegenerative diseases: mechanistic and therapeutic considerations. J Neurol Sci. 2012; 323(1-2):1-8. DOI: 10.1016/j.jns.2012.08.005. View

Rahman A, Ting K, Cullen K, Braidy N, Brew B, Guillemin G . The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One. 2009; 4(7):e6344. PMC: 2709912. DOI: 10.1371/journal.pone.0006344. View

Dubey K, Anand B, Temgire M, Kar K . Evidence of rapid coaggregation of globular proteins during amyloid formation. Biochemistry. 2014; 53(51):8001-4. DOI: 10.1021/bi501333q. View

Krause W, Halminski M, McDonald L, Dembure P, Salvo R, Freides D . Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man. J Clin Invest. 1985; 75(1):40-8. PMC: 423395. DOI: 10.1172/JCI111695. View

Rajbhandary A, Raymond D, Nilsson B . Self-Assembly, Hydrogelation, and Nanotube Formation by Cation-Modified Phenylalanine Derivatives. Langmuir. 2017; 33(23):5803-5813. DOI: 10.1021/acs.langmuir.7b00686. View

10.

Brundin L, Sellgren C, Lim C, Grit J, Palsson E, Landen M . An enzyme in the kynurenine pathway that governs vulnerability to suicidal behavior by regulating excitotoxicity and neuroinflammation. Transl Psychiatry. 2016; 6(8):e865. PMC: 5022080. DOI: 10.1038/tp.2016.133. View

11.

Guillemin G, Cullen K, Lim C, Smythe G, Garner B, Kapoor V . Characterization of the kynurenine pathway in human neurons. J Neurosci. 2007; 27(47):12884-92. PMC: 6673280. DOI: 10.1523/JNEUROSCI.4101-07.2007. View

12.

Chen Y, Guillemin G . Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res. 2011; 2:1-19. PMC: 3195227. DOI: 10.4137/ijtr.s2097. View

13.

Beagles K, Morrison P, Heyes M . Quinolinic acid in vivo synthesis rates, extracellular concentrations, and intercompartmental distributions in normal and immune-activated brain as determined by multiple-isotope microdialysis. J Neurochem. 1998; 70(1):281-91. DOI: 10.1046/j.1471-4159.1998.70010281.x. View

14.

Cleary M, Trefz F, Muntau A, Feillet F, van Spronsen F, Burlina A . Fluctuations in phenylalanine concentrations in phenylketonuria: a review of possible relationships with outcomes. Mol Genet Metab. 2013; 110(4):418-23. DOI: 10.1016/j.ymgme.2013.09.001. View

15.

Bleiholder C, Bowers M . The Solution Assembly of Biological Molecules Using Ion Mobility Methods: From Amino Acids to Amyloid β-Protein. Annu Rev Anal Chem (Palo Alto Calif). 2017; 10(1):365-386. PMC: 6287953. DOI: 10.1146/annurev-anchem-071114-040304. View

16.

Ragab G, Elshahaly M, Bardin T . Gout: An old disease in new perspective - A review. J Adv Res. 2017; 8(5):495-511. PMC: 5512152. DOI: 10.1016/j.jare.2017.04.008. View

17.

Erez A, DeBerardinis R . Metabolic dysregulation in monogenic disorders and cancer - finding method in madness. Nat Rev Cancer. 2015; 15(7):440-8. DOI: 10.1038/nrc3949. View

18.

Bartlett D, Lloyd C, McKiernan P, Newsome P . Early nitisinone treatment reduces the need for liver transplantation in children with tyrosinaemia type 1 and improves post-transplant renal function. J Inherit Metab Dis. 2014; 37(5):745-52. DOI: 10.1007/s10545-014-9683-x. View

19.

Morris M . Homocysteine and Alzheimer's disease. Lancet Neurol. 2003; 2(7):425-8. DOI: 10.1016/s1474-4422(03)00438-1. View

20.

Baldwin A, Knowles T, Tartaglia G, Fitzpatrick A, Devlin G, Shammas S . Metastability of native proteins and the phenomenon of amyloid formation. J Am Chem Soc. 2011; 133(36):14160-3. DOI: 10.1021/ja2017703. View